BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Alinaghi F, Tekin HG, Burisch J, Wu JJ, Thyssen JP, Egeberg A. Global Prevalence and Bidirectional Association Between Psoriasis and Inflammatory Bowel Disease—A Systematic Review and Meta-analysis. Journal of Crohn's and Colitis 2020;14:351-60. [DOI: 10.1093/ecco-jcc/jjz152] [Cited by in Crossref: 14] [Cited by in F6Publishing: 22] [Article Influence: 4.7] [Reference Citation Analysis]
Number Citing Articles
1 Freuer D, Linseisen J, Meisinger C. Association Between Inflammatory Bowel Disease and Both Psoriasis and Psoriatic Arthritis: A Bidirectional 2-Sample Mendelian Randomization Study. JAMA Dermatol. [DOI: 10.1001/jamadermatol.2022.3682] [Reference Citation Analysis]
2 Thein D, Egeberg A, Skov L, Loft N. Absolute and Relative Risk of New-Onset Psoriasis Associated With Tumor Necrosis Factor-α Inhibitor Treatment in Patients With Immune-Mediated Inflammatory Diseases: A Danish Nationwide Cohort Study. JAMA Dermatol 2022. [PMID: 35767240 DOI: 10.1001/jamadermatol.2022.2360] [Reference Citation Analysis]
3 Li Y, Guo J, Cao Z, Wu J. Causal Association Between Inflammatory Bowel Disease and Psoriasis: A Two-Sample Bidirectional Mendelian Randomization Study. Front Immunol 2022;13:916645. [PMID: 35757704 DOI: 10.3389/fimmu.2022.916645] [Reference Citation Analysis]
4 Bu J, Ding R, Zhou L, Chen X, Shen E. Epidemiology of Psoriasis and Comorbid Diseases: A Narrative Review. Front Immunol 2022;13:880201. [PMID: 35757712 DOI: 10.3389/fimmu.2022.880201] [Reference Citation Analysis]
5 Thye AY, Bah Y, Law JW, Tan LT, He Y, Wong S, Thurairajasingam S, Chan K, Lee L, Letchumanan V. Gut–Skin Axis: Unravelling the Connection between the Gut Microbiome and Psoriasis. Biomedicines 2022;10:1037. [DOI: 10.3390/biomedicines10051037] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
6 Sawayama H, Miyamoto Y, Yoshida N, Baba H. Essential updates 2020/2021: Colorectal diseases (benign)—Current topics in the surgical and medical treatment of benign colorectal diseases. Annals of Gastroent Surgery. [DOI: 10.1002/ags3.12548] [Reference Citation Analysis]
7 Bezzio C, Della Corte C, Vernero M, Di Luna I, Manes G, Saibeni S. Inflammatory bowel disease and immune-mediated inflammatory diseases: looking at the less frequent associations. Therap Adv Gastroenterol 2022;15:175628482211153. [DOI: 10.1177/17562848221115312] [Reference Citation Analysis]
8 Yan BX, Chen XY, Ye LR, Chen JQ, Zheng M, Man XY. Cutaneous and Systemic Psoriasis: Classifications and Classification for the Distinction. Front Med (Lausanne) 2021;8:649408. [PMID: 34722555 DOI: 10.3389/fmed.2021.649408] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
9 Yang M, Liu W, Deng Q, Liang Z, Wang Q. The incidence of psoriasis among smokers and/or former smokers inflammatory bowel diseases patients treated with tumor necrosis factor antagonist: A systematic review and meta-analysis. Medicine (Baltimore) 2021;100:e27510. [PMID: 34678884 DOI: 10.1097/MD.0000000000027510] [Reference Citation Analysis]
10 Maronese CA, Zelin E, Moltrasio C, Genovese G, Marzano AV. Genetic screening in new onset inflammatory bowel disease during anti-interleukin 17 therapy: unmet needs and call for action. Expert Opin Biol Ther 2021;21:1543-6. [PMID: 34448662 DOI: 10.1080/14712598.2021.1974395] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Bellinato F, Gisondi P, Girolomoni G. Risk of lymphohematologic malignancies in patients with chronic plaque psoriasis: A systematic review with meta-analysis. J Am Acad Dermatol 2021:S0190-9622(21)02212-X. [PMID: 34363908 DOI: 10.1016/j.jaad.2021.07.050] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
12 Hedin CRH, Sonkoly E, Eberhardson M, Ståhle M. Inflammatory bowel disease and psoriasis: modernizing the multidisciplinary approach. J Intern Med 2021;290:257-78. [PMID: 33942408 DOI: 10.1111/joim.13282] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
13 Hung YT, Le PH, Kuo CJ, Tang YC, Chiou MJ, Chiu CT, Kuo CF, Huang YH. The Temporal Relationships and Associations between Cutaneous Manifestations and Inflammatory Bowel Disease: A Nationwide Population-Based Cohort Study. J Clin Med 2021;10:1311. [PMID: 33810197 DOI: 10.3390/jcm10061311] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Wu J, Smogorzewski J. Ustekinumab for the treatment of paradoxical skin reactions and cutaneous manifestations of inflammatory bowel diseases. Dermatol Ther 2021;34:e14883. [PMID: 33594811 DOI: 10.1111/dth.14883] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
15 Jo UH, Lee JY, Lee H, Kim DY, Kang S, Koh SJ, Park H. Various skin manifestations related to inflammatory bowel disease: A nationwide cross-sectional study on the Korean population. J Dermatol 2021;48:431-8. [PMID: 33608949 DOI: 10.1111/1346-8138.15676] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
16 Kubanov AA, Bogdanova EV. Epidemiology of psoriasis in the Russian Federation according to the patient registry. Vestnik dermatologii i venerologii 2021;98:33-41. [DOI: 10.25208/vdv1268] [Reference Citation Analysis]
17 Kucharzik T, Koletzko S, Kannengiesser K, Dignass A. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms.Dtsch Arztebl Int. 2020;117:564-574. [PMID: 33148393 DOI: 10.3238/arztebl.2020.0564] [Cited by in Crossref: 4] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
18 Conforti C, Dianzani C, Zalaudek I, Cicala M, Persichetti P, Giuffrida R, Morariu S, Neagu N. Spotlight on the treatment armamentarium of concomitant psoriasis and inflammatory bowel disease: a systematic review. Journal of Dermatological Treatment. [DOI: 10.1080/09546634.2020.1836313] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
19 Marotto D, Atzeni F, Ardizzone S, Monteleone G, Giorgi V, Sarzi-Puttini P. Extra-intestinal manifestations of inflammatory bowel diseases. Pharmacol Res 2020;161:105206. [PMID: 32998068 DOI: 10.1016/j.phrs.2020.105206] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
20 Woo YR, Park CJ, Kang H, Kim JE. The Risk of Systemic Diseases in Those with Psoriasis and Psoriatic Arthritis: From Mechanisms to Clinic. Int J Mol Sci 2020;21:E7041. [PMID: 32987907 DOI: 10.3390/ijms21197041] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
21 Kovitwanichkanont T, Chong AH, Foley P. Beyond skin deep: addressing comorbidities in psoriasis. Med J Aust 2020;212:528-34. [PMID: 32388913 DOI: 10.5694/mja2.50591] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
22 Frew JW. Anti–Saccharomyces cervisiae antibodies in hidradenitis suppurativa: More than a gut feeling. Journal of Allergy and Clinical Immunology 2020;146:458. [DOI: 10.1016/j.jaci.2020.03.022] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]